Immunohistochemical Expression of ER, PR and HER2/neu in Endometrial Carcinoma
- 37 Downloads
Endometrial carcinoma (EC) is the third common gynecologic cancer in India. It consists of two major histological types: the most common endometrioid or type I EC and non-endometrioid or type II EC. They are biologically distinct, and various markers have been proposed as prognostic biomarkers in EC besides clinical and pathological features.
To study the immunohistochemical (IHC) expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2/neu) in EC and to correlate them with various clinicopathological parameters.
IHC study of ER, PR and HER2/neu was performed on 35 cases of histopathologically diagnosed EC in hysterectomy specimens for a period of 4 years from 2014 to 2017.
Majority of the patients were aged 51–60 years, and the common comorbid conditions were type 2 diabetes mellitus, hypertension and obesity. Histologically, 31 (88.57%) cases were of type 1 EC and 4 (11.43%) were of type II EC; in type II EC, 2 (5.7%) cases were papillary serous carcinoma and the remaining two cases each were malignant mixed Mullerian tumor (MMMT) and dedifferentiated carcinoma (DC). ER expression was observed in 29 cases (82.9%) and was statistically significant with tumor stage, tumor grade, histological type and intraglandular necrosis. PR expression was seen in 22 (62.9%) cases and showed significant association with tumor grade, myometrial invasion and histological type. HER2/neu was expressed in one case.
Establishing the diagnosis of molecular subtype of EC with limited markers, namely ER/PR, HER2/neu expression similar to breast cancer, may be useful to determine the treatment and prognosis, especially in developing countries. Studies with larger sample sizes may elucidate their role, which was the limitation in this study.
KeywordsEndometrial cancer Immunohistochemistry ER/PR HER2/neu
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Wilczyński M, Danielska J, Wilczyński J. An update of the classical Bokhman’s dualistic model of endometrial cancer. PrzMenopauzalny. 2016;15(2):63–8.Google Scholar
- 7.Baker J, Obermair A, Gebski V, Janda M. Efficacy of oral or intrauterine device- delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol. 2012;125(1):263–70.CrossRefGoogle Scholar
- 11.Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from national surgical adjuvant breast and bowel project protocol B-06. J Clin Oncol. 1988;6(7):1076–87.CrossRefGoogle Scholar
- 13.Binder PS, Mutch DG. Update on prognostic markers for endometrial cancer. Womens Health. 2014;10(3):277–88.Google Scholar
- 15.Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A Phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study. Gynecol Oncol. 2004;92(3):744–51.CrossRefGoogle Scholar